The combination of belzutifan plus lenvatinib significantly improved outcomes for patients with clear cell renal cell carcinoma who progressed following immunotherapy compared with cabozantinib ...
LITESPARK-011 demonstrated improved progression-free survival with the combination of belzutifan plus lenvatinib vs ...
22h
Exelixis Highlights Zanzalintinib RCC Trials, Sequencing Debate, and December CRC PDUFA at Leerink
Exelixis (NASDAQ:EXEL) executives and investors spent part of the discussion at a Leerink event focusing on recent renal cell ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Combining ...
Doctor taking notes. The median time to first onset of key adverse reactions was within 5 months of starting lenvatinib-pembrolizumab. The following article features coverage from the International ...
MedPage Today on MSN
Improved PFS in Advanced Kidney Cancer With Antiangiogenic Combination
Belzutifan-lenvatinib slows progression versus cabozantinib with much longer response dura ...
The LEAP-017 trial results presented at ESMO GI 2023 are explored by Dr Marshall. John L. Marshall, MD: There is an early observation that VEGF [vascular endothelial growth factor] inhibition along ...
Learn everything you need to know about Lenvatinib-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...
At the final analysis, the coprimary endpoint of overall survival was not met. Topline data were announced from a phase 3 trial evaluating pembrolizumab (Keytruda ®) plus lenvatinib (Lenvima ®) in ...
The phase 3 LEAP-011 study evaluated pembrolizumab plus lenvatinib vs placebo in 441 adults with histologically confirmed, locally advanced or metastatic urothelial carcinoma. The following article ...
Please provide your email address to receive an email when new articles are posted on . Lenvatinib plus pembrolizumab conferred significantly longer PFS and OS than chemotherapy among women with ...
The Food and Drug Administration (FDA) has approved the combination of pembrolizumab (Keytruda, Merck Sharp & Dohme) with lenvatinib (Lenvima, Eisai Inc) for the first-line treatment of adult patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results